Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Forum of Allergy & Rhinology|June 2, 2018
EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitisJames N Palmer, Kraig W Jacobson, John C Messina, et al.
Hormones and Behavior|May 12, 2018
Saliva oxytocin measures do not reflect peripheral plasma concentrations after intranasal oxytocin administration in menDaniel S Quintana, Lars T Westlye, Knut T Smerud, et al.
The Journal of Pharmacy and Pharmacology|August 26, 2009
Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional deviceRemy Luthringer, Per G Djupesland, Colin D Sheldrake, et al.
The Journal of Pharmacy and Pharmacology|October 13, 2006
Intranasal midazolam: a comparison of two delivery devices in human volunteersOla Dale, Turid Nilsen, Thorsteinn Loftsson, et al.
American Journal of Rhinology & Allergy|November 28, 2018
NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal PolypsRaj Sindwani, Joseph K Han, Daniel F Soteres, et al.
Headache|October 31, 2014
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study)Roger K Cady, Peter J McAllister, Egilius L H Spierings, et al.
Headache|May 6, 2015
AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacksStewart J Tepper, Roger K Cady, Stephen Silberstein, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 17, 2018
Low-dose intranasal oxytocin delivered with Breath Powered device modulates pupil diameter and amygdala activity: a randomized controlled pupillometry and fMRI studyDaniel S Quintana, Lars T Westlye, Dag Alnæs, et al.
Psychoneuroendocrinology|April 24, 2016
Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trialDaniel S Quintana, Lars T Westlye, Dag Alnæs, et al.
Pageof 2